1. Home
  2. ATYR vs HBIO Comparison

ATYR vs HBIO Comparison

Compare ATYR & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • HBIO
  • Stock Information
  • Founded
  • ATYR 2005
  • HBIO 1901
  • Country
  • ATYR United States
  • HBIO United States
  • Employees
  • ATYR N/A
  • HBIO N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • HBIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • ATYR Health Care
  • HBIO Industrials
  • Exchange
  • ATYR Nasdaq
  • HBIO Nasdaq
  • Market Cap
  • ATYR 126.3M
  • HBIO 117.7M
  • IPO Year
  • ATYR 2015
  • HBIO 2000
  • Fundamental
  • Price
  • ATYR $2.23
  • HBIO $2.53
  • Analyst Decision
  • ATYR Strong Buy
  • HBIO
  • Analyst Count
  • ATYR 4
  • HBIO 0
  • Target Price
  • ATYR $19.25
  • HBIO N/A
  • AVG Volume (30 Days)
  • ATYR 586.5K
  • HBIO 133.4K
  • Earning Date
  • ATYR 11-07-2024
  • HBIO 11-05-2024
  • Dividend Yield
  • ATYR N/A
  • HBIO N/A
  • EPS Growth
  • ATYR N/A
  • HBIO N/A
  • EPS
  • ATYR N/A
  • HBIO N/A
  • Revenue
  • ATYR $588,000.00
  • HBIO $101,125,000.00
  • Revenue This Year
  • ATYR N/A
  • HBIO N/A
  • Revenue Next Year
  • ATYR $2,057.88
  • HBIO $2.68
  • P/E Ratio
  • ATYR N/A
  • HBIO N/A
  • Revenue Growth
  • ATYR N/A
  • HBIO N/A
  • 52 Week Low
  • ATYR $1.08
  • HBIO $2.32
  • 52 Week High
  • ATYR $2.50
  • HBIO $5.56
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 74.37
  • HBIO 44.75
  • Support Level
  • ATYR $1.83
  • HBIO $2.38
  • Resistance Level
  • ATYR $1.96
  • HBIO $2.53
  • Average True Range (ATR)
  • ATYR 0.09
  • HBIO 0.12
  • MACD
  • ATYR 0.05
  • HBIO -0.01
  • Stochastic Oscillator
  • ATYR 93.33
  • HBIO 51.22

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Share on Social Networks: